Hammer SM, Squires KE, Hughes MD.
et al. A controlled trial of two nucleoside analogues plus indinavir in persons
with human immunodeficiency virus infection and CD4 cell counts of 200 per
cubic millimeter or less. N Engl J Med.1997;337:725-733.
Cameron DW, Heath-Chiozzi M, Danner S.
et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1
Montaner JS, Reiss P, Cooper D.
et al. A randomized, double-blind trial comparing combinations of nevirapine,
didanosine, and zidovudine for HIV-infected patients. JAMA.1998;279:930-937.
Carpenter CC, Cooper DA, Fischl MA.
et al. Antiretroviral therapy in adults. JAMA.2000;283:381-390.
Gazzard B, Moyle G. 1998 revision to the British HIV Association guidelines for antiretroviral
treatment of HIV seropositive individuals. Lancet.1998;352:314-316.
Panel on Clinical Practices for the Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in
HIV-Infected Adults and Adolescents. Washington, DC: US Dept of Health and Human Services/Henry J. Kaiser
Family Foundation; January 2000.
Grabar S, Le Moing V, Goujard C.
et al. Clinical outcome of patients with HIV-1 infection according to immunologic
and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med.2000;133:401-410.
Volberding PA, Lagokos SW, Grimes JM.
et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic
HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. N Engl J Med.1995;333:401-407.
Mellors JW, Rinaldo Jr CR, Gupta P.
et al. Prognosis in HIV-1 infection predicted by the quantity of virus in
Mellors JW, Munoz A, Giorgi JV.
et al. Plasma viral load and CD4 + lymphocytes as prognostic markers of HIV-1
infection. Ann Intern Med.1997;126:946-954.
Phillips AN, Staszewski Not Available, Weber R.
et al. Viral load changes in response to antiretroviral therapy according
to the baseline CD4 lymphocyte count and viral load. AIDS.2000;14(suppl 4):S3.
Cozzi-Lepri A, Phillips AN, d' Arminio-Monforte A.
et al. When to start HAART in chronically HIV-infected patients? AIDS.2000;14(suppl 4):S3.
Hogg RS, Yip B, Kully C.
et al. Improved survival among HIV-infected patients after initiation of triple-drug
antiretroviral regimens. CMAJ.1999;160:659-665.
Hogg RS, Heath KV, Yip B.
et al. Improved survival among HIV-infected individuals following initiation
of antiretroviral therapy. JAMA.1998;279:450-454.
Not Available. Therapeutic Guidelines for the Treatment of HIV/AIDS and Related
Conditions. Vancouver: British Columbia: Centre for Excellence in HIV/AIDS; 1999.
Carpenter CC, Fischl MA, Hammer SM.
et al. Antiretroviral therapy for HIV infection in 1996. JAMA.1996;276:146-154.
Carpenter CC, Fischl MA, Hammer SM.
et al. Antiretroviral therapy for HIV infection in 1997. JAMA.1997;277:1962-1969.
World Health Organization. Acquired immune deficiency syndrome (AIDS): interim proposal for a
WHO staging system for HIV infection and disease. Wkly Epidemol Rec.1990;65:221-228.
Cox DR. Regression models and life tables. J R Stat Soc B.1972;34:187-202.
Pedersen C, Gerstoft J, Tauris P.
et al. Trends in survival of Danish AIDS patients from 1981 to 1989. AIDS.1990;4:1111-1116.
Lemp GF, Payne SF, Neal D.
et al. Survival trends for patients with AIDS. JAMA.1990;263:402-406.
Saah AJ, Hoover DR, He Y.
et al. Factors influencing survival after AIDS. J Acquir Immune Defic Syndr.1994;7:287-295.
Bindels PJ, Krol A, Roos M.
et al. The predictive value of T cell function in vitro and pre-AIDS zidovudine
use for survival after AIDS diagnosis in a cohort of homosexual men in Amsterdam. J Infect Dis.1995;172:97-104.
Marschner IC, Collier AC, Coombs RW.
et al. Use of changes in plasma levels of human immunodeficiency virus type
1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis.1998;177:40-47.
O'Brien WA, Hartigan PM, Martin D.
et al. Changes in plasma HIV-1 RNA and CD4 + lymphocyte counts and the risk
of progression to AIDS. N Engl J Med.1996;334:426-431.
Craib KJ, Strathdee SA, Hogg RS.
et al. Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after
seroconversion. J Infect Dis.1997;176:798-800.
Hogg RS, Yip B, Chan K.
et al. Nonadherence to triple combination therapy is predictive of AIDS progression
and death in HIV-positive men and women. From: 7th Conference on Retroviruses and Opportunistic Infections;
January 30-Feburary 2, 2000; San Francisco, Calif. Abstract 73.
Lee LM, Karon JM, Selik R.
et al. Survival after AIDS diagnosis in adolescents and adults during the
treatment era, United States, 1984-1997. JAMA.2001;285:1308-1315.
Chen R, Westfall A, Cloud G.
et al. Long-term survival after initiation of antiretroviral therapy. From: 8th Conference on Retroviruses and Opportunistic Infections;
February 4-8, 2001; Chicago, Ill. Abstract 341.
Sterling TR, Chaisson RE, Bartlett JG, Moore RD. CD4+ lymphocyte level is better than HIV-1 plasma viral
load in determining when to initiate HAART. From: 8th Conference on Retroviruses and Opportunistic Infections;
February 4-8, 2001; Chicago, Ill. Abstract 519.
Kaplan J, Hanson D, Karon J.
et al. Late initiation of antiretroviral therapy (at CD4 + lymphocyte count
<200 cells/mL) is associated with increased risk of death. From: 8th Conference on Retroviruses and Opportunistic Infections;
February 4-8, 2001; Chicago, Ill. Abstract 520.